Response to: Bayesian Reappraisal of ACNS0332 and ACNS0334 Strengthens Subgroup Treatment Effects in High-Risk Pediatric Group 3 Medulloblastoma.

IF 13.4 1区医学 Q1 CLINICAL NEUROLOGY

Neuro-oncology Pub Date : 2025-09-29 DOI:10.1093/neuonc/noaf212

Guolian Kang, Sarah E S Leary, Arzu Onar-Thomas, Yimei Li

引用次数: 0

查看原文本刊更多论文

对ACNS0332和ACNS0334的贝叶斯重新评价加强了高危儿童3组髓母细胞瘤亚组治疗效果的回应

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuro-oncology 医学-临床神经学

CiteScore

27.20

自引率

6.30%

发文量

1434

审稿时长

3-8 weeks

期刊介绍： Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.